The immune system is important for elimination of residual leukemic cells during acute myeloid leukemia (AML) therapy. Anti-leukemia immune response can be inhibited by various mechanisms leading to immune evasion and disease relapse. Selected markers of immune escape were analyzed on AML cells from leukapheresis at diagnosis (N = 53). Hierarchical clustering of AML immunophenotypes yielded distinct genetic clusters. In the absence of DNMT3A mutation, NPM1 mutation was associated with decreased HLA expression and low levels of other markers (CLIP, PD-L1, TIM-3). Analysis of an independent cohort confirmed decreased levels of HLA transcripts in patients with NPM1 mutation. Samples with combined NPM1 and DNMT3A mutations had high CLIP surface amount suggesting reduced antigen presentation. TIM-3 transcript correlated not only with TIM-3 surface protein but also with CLIP and PD-L1. In our cohort, high levels of TIM-3/PD-L1/CLIP were associated with lower survival. Our results suggest that AML genotype is related to blast immunophenotype, and that high TIM-3 transcript levels in AML blasts could be a marker of immune escape. Cellular pathways regulating resistance to the immune system might contribute to the predicted response to standard therapy of patients in specific AML subgroups and should be targeted to improve AML treatment.

Clinical Department Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Apheresis Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Cytogenetics Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Gene Immunotherapy Research Institute of Hematology and Blood Transfusion Prague Czech Republic

Department of Proteomics Institute of Hematology and Blood Transfusion Prague Czech Republic

Institute of Clinical and Experimental Hematology 1st Faculty of Medicine Charles University Prague Czech Republic

Medical Clinic 1 Division Hematology Cell Therapy and Medical Oncology University Hospital Carl Gustav Carus Technical University Dresden Dresden Germany

000      

00000naa a2200000 a 4500

001      

bmc22018457

003      

CZ-PrNML

005      

20220804134759.0

007      

ta

008      

220720s2022 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1080/2162402X.2022.2073050 $2 doi

035    __

$a (PubMed)35558161

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Kuželová, Kateřina $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000296286255 $7 xx0115456

245    10

$a NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia / $c K. Kuželová, B. Brodská, J. Marková, M. Petráčková, J. Schetelig, Š. Ransdorfová, Z. Gašová, C. Šálek

520    9_

$a The immune system is important for elimination of residual leukemic cells during acute myeloid leukemia (AML) therapy. Anti-leukemia immune response can be inhibited by various mechanisms leading to immune evasion and disease relapse. Selected markers of immune escape were analyzed on AML cells from leukapheresis at diagnosis (N = 53). Hierarchical clustering of AML immunophenotypes yielded distinct genetic clusters. In the absence of DNMT3A mutation, NPM1 mutation was associated with decreased HLA expression and low levels of other markers (CLIP, PD-L1, TIM-3). Analysis of an independent cohort confirmed decreased levels of HLA transcripts in patients with NPM1 mutation. Samples with combined NPM1 and DNMT3A mutations had high CLIP surface amount suggesting reduced antigen presentation. TIM-3 transcript correlated not only with TIM-3 surface protein but also with CLIP and PD-L1. In our cohort, high levels of TIM-3/PD-L1/CLIP were associated with lower survival. Our results suggest that AML genotype is related to blast immunophenotype, and that high TIM-3 transcript levels in AML blasts could be a marker of immune escape. Cellular pathways regulating resistance to the immune system might contribute to the predicted response to standard therapy of patients in specific AML subgroups and should be targeted to improve AML treatment.

650    _2

$a antigeny CD274 $x genetika $7 D060890

650    _2

$a biologické markery $7 D015415

650    12

$a DNA methyltransferasa 3A $x genetika $7 D000090205

650    _2

$a buněčný receptor 2 viru hepatitidy A $x genetika $7 D000072597

650    _2

$a lidé $7 D006801

650    12

$a akutní myeloidní leukemie $x diagnóza $x genetika $7 D015470

650    _2

$a mutace $7 D009154

650    12

$a nukleofosmin $x genetika $7 D000090243

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Brodská, Barbora $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/000000023703594X

700    1_

$a Marková, Jana $u Clinical Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

700    1_

$a Petráčková, Martina $u Department of Gene Immunotherapy Research, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

700    1_

$a Schetelig, Johannes $u Medical Clinic I, Division Hematology, Cell Therapy, and Medical Oncology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany

700    1_

$a Ransdorfová, Šárka $u Department of Cytogenetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

700    1_

$a Gašová, Zdenka $u Department of Apheresis, Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Šálek, Cyril $u Clinical Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

773    0_

$w MED00190079 $t Oncoimmunology $x 2162-402X $g Roč. 11, č. 1 (2022), s. 2073050

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35558161 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220720 $b ABA008

991    __

$a 20220804134753 $b ABA008

999    __

$a ok $b bmc $g 1822171 $s 1169700

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 11 $c 1 $d 2073050 $e 20220506 $i 2162-402X $m Oncoimmunology $n Oncoimmunology $x MED00190079

LZP    __

$a Pubmed-20220720